Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Diagnostic Test for Alzheimer's Disease
View Government-Owned Inventions; Availability for Licensing
View National Institute of Child Health and Human Development: Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for Novel Progesterone Antagonists and Pharmaceutical Compositions Thereof There is no deadline by which license applications must be received. CRADA proposals must be received on or before May 14, 1997.
View Prospective Grant of Exclusive License: Vaccines for Dengue and Other Flaviviruses
View Prospective Grant of Exclusive License: Particle-Medicated Gene Delivery DNA Vaccines Against Dengue and Other Flavivirus Infections
View Medicare and Medicaid Programs; Small Business Innovation Research Grants for Fiscal Year 1997 Grant applications must be submitted by April 29, 1997, in order to be considered under the fiscal year (FY) 1997 annual funding cycle.
View Government-Owned Inventions; Availability for Licensing
View National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Monoclonal Antibodies to a Tumor-Specific Growth Factor for the Diagnosis and Prognosis of Premalignant Lesion and Cancer
View National Center for Research Resources: Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of Technologies and Applications for Spatial and Temporal Control of Gene Expression Using a Heat Shock Protein Promoter in Combination With Local Heat There is no deadline by which license applications or CRADA proposals must be received.
View National Eye Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases: Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Use of Antiflammins There is no deadline by which license applications must be received. CRADA proposals must be received on or before April 8, 1997.
View Prospective Grant of Exclusive License: Gossypol Acetica Acid for the Treatment of Cancer
View Prospective Grant of Exclusive License: Intra-Urethral Prosthetic Sphincter Valve and Intra-Urethral Valve with Integral Spring
View National Institute of Environmental Health Sciences: Opportunity for a Cooperative Research and Development Agreement (CRADA) and License for the Development of KAI1 in Gene Therapy Protocols for the Treatment of Metastatic Disease Capability statements must be received by NIH on or before January 31, 1997.
View National Cancer Institute and the Food and Drug Administration In view of the important priority of developing new agents for the treatment of infectious disease and related malignancies, interested parties should notify this office in writing no later than January 21, 1997. Respondents will then be provided an additional 30 days for the filing of formal proposals.
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Fusion Proteins That Include Antibody and Non-Antibody Portions In view of the important priority of developing new agents for the treatment or prevention of cancer, interested parties should notify this office in writing no later than [FR: insert date 60 days after date of publication]. Respondents will then be provided an additional 30 days for the filing of formal proposals.
View Prospective Grant of a Partially Exclusive License: Pseudomonas- Exotoxin-Based Fusion Protein Cancer Therapy
View Prospective Grant of Exclusive License: Therapeutic Uses of Microtubule Stabilizing Agents Including Taxol (Paclitaxel) for Fibroproliferative Vascular Diseases Including Atherosclerosis and Restenosis and Excluding Cancer
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for B-Cell Lymphoma Tumor Specific Antigen Studies In view of the high interest in developing Anti-Cancer Vaccines in general, interested parties should notify the NCI Office of Technology Development in writing no later than December 4, 1996.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Novel Method of O- Demethylation and N-Deprotection of Opioid Compounds
View Prospective Grant of Exclusive License: Synthesis of Medical Opiate Compounds
View Prospective Grant of Exclusive License: Therapeutic Polyamines
View Prospective Grant of Exclusive License: Immunotoxins With In-Vivo T Cell Suppressant Activity and Methods of Use and Immunotoxins
View Prospective Grant of Exclusive License: Pharmaceuticals for the Treatment of Autoimmune Disease and Transplant Rejection 6/07/93 (2) Method of Treating Autoimmune Diseases and Transplantation Rejection
View Opportunity for a Cooperative Research and Development Agreement